Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase Bα/Akt1

Livius V. Duscio, Zvonimir S Katusic

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Tetrahydrobiopterin (BH4) is an essential cofactor required for enzymatic activity of endothelial NO synthase. Recently, it has been shown that vascular protective effects of erythropoietin (EPO) are dependent on activation of endothelial NO synthase. Therefore, our objective was to characterize the effect of EPO on the biosynthesis of BH4 in the vascular wall. Incubation of isolated C57BL/6J mouse aortas for 18 hours with recombinant human EPO (1 to 50 U/mL) caused a concentration-dependent increase in intracellular BH4 levels and activity of GTP-cyclohydrolase I. Maximal biosynthesis of BH4 was detected at therapeutic concentrations of 5 U/mL. Removal of the endothelium abolished EPO-induced biosynthesis of BH4 demonstrating that the vascular endothelium is a major source of BH4. Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH4 biosynthesis stimulated by EPO. The stimulatory effect of EPO on vascular GTP-cyclohydrolase I activity, BH4 production, and phosphorylation of endothelial NO synthase was also detected in vivo in mice treated with recombinant human EPO. These effects of EPO were abolished in protein kinase Bα/Akt1-deficient mice. In addition, EPO significantly increased systolic blood pressure and the number of circulating platelets in Akt1-deficient mice. Our results demonstrate that EPO stimulates biosynthesis of BH4 in vascular endothelium and that the increase in BH4 levels is caused by de novo biosynthesis of BH4 via the phosphatidylinositol 3-kinase/Akt1 pathway. This effect is most likely designed to provide optimal intracellular concentration of the cofactor necessary for EPO-induced elevation of endothelial NO synthase activity.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalHypertension
Volume52
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Proto-Oncogene Proteins c-akt
Erythropoietin
Nitric Oxide Synthase
GTP Cyclohydrolase
Phosphatidylinositol 3-Kinase
Blood Vessels
Vascular Endothelium
sapropterin
Blood Pressure
Platelet Count
Inbred C57BL Mouse
Endothelium
Aorta
Phosphorylation

Keywords

  • Endothelium
  • Erythropoietin
  • GTP-cyclohydrolase I
  • Mice
  • Protein kinase B
  • Tetrahydrobiopterin
  • Vasculature

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase Bα/Akt1. / Duscio, Livius V.; Katusic, Zvonimir S.

In: Hypertension, Vol. 52, No. 1, 01.07.2008, p. 93-99.

Research output: Contribution to journalArticle

@article{8e670d5365824d82aa16a0e82082c3ef,
title = "Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase Bα/Akt1",
abstract = "Tetrahydrobiopterin (BH4) is an essential cofactor required for enzymatic activity of endothelial NO synthase. Recently, it has been shown that vascular protective effects of erythropoietin (EPO) are dependent on activation of endothelial NO synthase. Therefore, our objective was to characterize the effect of EPO on the biosynthesis of BH4 in the vascular wall. Incubation of isolated C57BL/6J mouse aortas for 18 hours with recombinant human EPO (1 to 50 U/mL) caused a concentration-dependent increase in intracellular BH4 levels and activity of GTP-cyclohydrolase I. Maximal biosynthesis of BH4 was detected at therapeutic concentrations of 5 U/mL. Removal of the endothelium abolished EPO-induced biosynthesis of BH4 demonstrating that the vascular endothelium is a major source of BH4. Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH4 biosynthesis stimulated by EPO. The stimulatory effect of EPO on vascular GTP-cyclohydrolase I activity, BH4 production, and phosphorylation of endothelial NO synthase was also detected in vivo in mice treated with recombinant human EPO. These effects of EPO were abolished in protein kinase Bα/Akt1-deficient mice. In addition, EPO significantly increased systolic blood pressure and the number of circulating platelets in Akt1-deficient mice. Our results demonstrate that EPO stimulates biosynthesis of BH4 in vascular endothelium and that the increase in BH4 levels is caused by de novo biosynthesis of BH4 via the phosphatidylinositol 3-kinase/Akt1 pathway. This effect is most likely designed to provide optimal intracellular concentration of the cofactor necessary for EPO-induced elevation of endothelial NO synthase activity.",
keywords = "Endothelium, Erythropoietin, GTP-cyclohydrolase I, Mice, Protein kinase B, Tetrahydrobiopterin, Vasculature",
author = "Duscio, {Livius V.} and Katusic, {Zvonimir S}",
year = "2008",
month = "7",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.108.114041",
language = "English (US)",
volume = "52",
pages = "93--99",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Erythropoietin increases endothelial biosynthesis of tetrahydrobiopterin by activation of protein kinase Bα/Akt1

AU - Duscio, Livius V.

AU - Katusic, Zvonimir S

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Tetrahydrobiopterin (BH4) is an essential cofactor required for enzymatic activity of endothelial NO synthase. Recently, it has been shown that vascular protective effects of erythropoietin (EPO) are dependent on activation of endothelial NO synthase. Therefore, our objective was to characterize the effect of EPO on the biosynthesis of BH4 in the vascular wall. Incubation of isolated C57BL/6J mouse aortas for 18 hours with recombinant human EPO (1 to 50 U/mL) caused a concentration-dependent increase in intracellular BH4 levels and activity of GTP-cyclohydrolase I. Maximal biosynthesis of BH4 was detected at therapeutic concentrations of 5 U/mL. Removal of the endothelium abolished EPO-induced biosynthesis of BH4 demonstrating that the vascular endothelium is a major source of BH4. Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH4 biosynthesis stimulated by EPO. The stimulatory effect of EPO on vascular GTP-cyclohydrolase I activity, BH4 production, and phosphorylation of endothelial NO synthase was also detected in vivo in mice treated with recombinant human EPO. These effects of EPO were abolished in protein kinase Bα/Akt1-deficient mice. In addition, EPO significantly increased systolic blood pressure and the number of circulating platelets in Akt1-deficient mice. Our results demonstrate that EPO stimulates biosynthesis of BH4 in vascular endothelium and that the increase in BH4 levels is caused by de novo biosynthesis of BH4 via the phosphatidylinositol 3-kinase/Akt1 pathway. This effect is most likely designed to provide optimal intracellular concentration of the cofactor necessary for EPO-induced elevation of endothelial NO synthase activity.

AB - Tetrahydrobiopterin (BH4) is an essential cofactor required for enzymatic activity of endothelial NO synthase. Recently, it has been shown that vascular protective effects of erythropoietin (EPO) are dependent on activation of endothelial NO synthase. Therefore, our objective was to characterize the effect of EPO on the biosynthesis of BH4 in the vascular wall. Incubation of isolated C57BL/6J mouse aortas for 18 hours with recombinant human EPO (1 to 50 U/mL) caused a concentration-dependent increase in intracellular BH4 levels and activity of GTP-cyclohydrolase I. Maximal biosynthesis of BH4 was detected at therapeutic concentrations of 5 U/mL. Removal of the endothelium abolished EPO-induced biosynthesis of BH4 demonstrating that the vascular endothelium is a major source of BH4. Treatment with a selective phosphatidylinositol 3-kinase inhibitor wortmannin significantly reduced BH4 biosynthesis stimulated by EPO. The stimulatory effect of EPO on vascular GTP-cyclohydrolase I activity, BH4 production, and phosphorylation of endothelial NO synthase was also detected in vivo in mice treated with recombinant human EPO. These effects of EPO were abolished in protein kinase Bα/Akt1-deficient mice. In addition, EPO significantly increased systolic blood pressure and the number of circulating platelets in Akt1-deficient mice. Our results demonstrate that EPO stimulates biosynthesis of BH4 in vascular endothelium and that the increase in BH4 levels is caused by de novo biosynthesis of BH4 via the phosphatidylinositol 3-kinase/Akt1 pathway. This effect is most likely designed to provide optimal intracellular concentration of the cofactor necessary for EPO-induced elevation of endothelial NO synthase activity.

KW - Endothelium

KW - Erythropoietin

KW - GTP-cyclohydrolase I

KW - Mice

KW - Protein kinase B

KW - Tetrahydrobiopterin

KW - Vasculature

UR - http://www.scopus.com/inward/record.url?scp=46449113646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46449113646&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.108.114041

DO - 10.1161/HYPERTENSIONAHA.108.114041

M3 - Article

C2 - 18519842

AN - SCOPUS:46449113646

VL - 52

SP - 93

EP - 99

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 1

ER -